CureVac N.V.

+4.20 (+10.30%)
Earnings Announcements

Curevac Reports Revenue Of Eur 29.3 Mln and Eur 61.8 Mln For 3 and 9 Months Ended Sept 30

Published: 11/18/2021 21:30 GMT
CureVac N.V. (CVAC) - Curevac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update.
Revenues Amounted to EUR 29.3 Million, EUR 61.8 Million for Three,nine Months Ended Sept 30, 2021, Respectively, Increase of EUR 24.1 Million,eur 19.0 Million.
Operating Loss Amounted to EUR 143.1 Million and EUR 406.7 Million for Three and Nine Months Ended September 30, 2021.
Cash Position of EUR 1.06 Billion As of September 30, 2021.
Continues to Assess Supplier Commitments Related to Withdrawal of First-generation Covid-19 Vaccine Candidate.
Based on Communication From Ema in October 2021, Curevac Estimated That Earliest Possible Approval of Cvncov Would Come in Q2 of 2022.
By This Time, Curevac and Gsk Expect Candidates From Second-generation Vaccine Program to Be Progressing Through Clinical Development.
As a Direct Consequence of Withdrawal of Cvncov, Existing Advanced Purchase Agreement With European Commission Will Cease.
Revenue is expected to be $16.02 Million
Adjusted EPS is expected to be -$0.72

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.